CYP2D6 genotypes in Spanish women with breast cancer

被引：26

作者：

Ladona, MG

Abildua, RE

Ladero, JM

Roman, JM

Plaza, MA

Agundez, JAG

Munoz, JJ

Benitez, J

机构：

[1] UNIV COMPLUTENSE MADRID, DEPT PHARMACOL, MADRID, SPAIN

[2] UNIV EXTREMADURA, DEPT PHARMACOL, BADAJOZ, SPAIN

[3] SAN CARLOS UNIV HOSP, SERV GASTROENTEROL, MADRID, SPAIN

[4] SAN CARLOS UNIV HOSP, SERV OBSTET & GYNAECOL, BREAST UNIT, MADRID, SPAIN

来源：

CANCER LETTERS | 1996年 / 99卷 / 01期

关键词：

CYP2D6; P4502D6; breast cancer; debrisoquine; polymorphism;

D O I：

10.1016/0304-3835(95)04033-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Wild type and three mutated alleles of the polymorphic CYP2D6 gene were studied in genomic DNA samples from 187 women with breast carcinoma and 151 healthy women by a mutation-specific polymerase chain reaction. The prevalence of the enzyme-inactivating CYP2D6(B) allele was higher among patients (18.2%) than in controls (11.6%; OR = 1.7; 95% c.i. = 1.14-3.13; P = 0.018). This excess was more marked in postmenopausal patients (19.8%, P = 0.0086) and in patients with non-ductal infiltrating carcinomas (25.8%, P = 0.003). The percentage of carriers of only one active gene (heterozygote extensive metabolizers) was higher in patients (31% vs. 19.9%; OR = 1.81; 95% c.i. = 1.06-3.11; P = 0.02). The CYP2D6(B)-carrier state may be related to a greater risk of breast cancer in women.

引用

页码：23 / 28

页数：6

共 50 条

[31] Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer
Brauch, Hiltrud
Schwab, Matthias
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (04) : 695 - 703
[32] CYP2D6 polymorphism in a Gabonese population:: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype
Panserat, S
Sica, L
Gérard, N
Mathieu, H
Jacqz-Aigrain, E
Krishnamoorthy, R
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) : 121 - 124
[33] Resequencing CYP2D6 gene in Indian population: CYP2D6*41 identified as the major reduced function allele
Manoharan, Aarthi
Shewade, Deepak Gopal
Ravindranath, Pradeep Anand
Rajkumar, Ravi Philip
Ramprasad, Vedam L.
Adithan, Surendiran
Damodaran, Solai Elango
PHARMACOGENOMICS, 2019, 20 (10) : 719 - 730
[34] The cytochrome P450 2D6 (CYP2D6) gene polymorphism among breast and head and neck cancer patients
Topic, E
Stefanovic, M
Ivanisevic, AM
Petrinovic, R
Curcic, I
CLINICA CHIMICA ACTA, 2000, 296 (1-2) : 101 - 109
[35] CYP2D6 gene polymorphisms and breast cancer risk in Moroccan population: A case-control study
Elouilamine, Ezohra
El Akil, Soumaya
Aznag, Fatima Zahra
Izaabel, El Hassan
GENE REPORTS, 2020, 20
[36] The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population
T. Fukuda
Y. Nishida
Q. Zhou
I. Yamamoto
S. Kondo
J. Azuma
European Journal of Clinical Pharmacology, 2000, 56 : 175 - 180
[37] The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population
Fukuda, T
Nishida, Y
Zhou, Q
Yamamoto, I
Kondo, S
Azuma, J
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (02) : 175 - 180
[38] Profiling of pharmacogenomic variants in CYP2D6 and DPYD in indigenous Arab breast cancer patients
Alsulaiman, Abdullah
Chu, Hoyin
Al-Jumaan, Mohammed
Alyahya, Mohammed
Al Marzooq, Yousef
Almulhim, Fatmah
Vatte, Chittibabu
Alnimer, Areej
Almuhanna, Afnan
Al-Ali, Amein
AlDubayan, Saud H.
PHARMACOGENOMICS, 2023, 24 (07) : 411 - 423
[39] CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients
Barriere, J.
Formento, J. -L.
Milano, G.
Ferrero, J. -M.
BULLETIN DU CANCER, 2010, 97 (03) : 311 - 320
[40] CYP2D6 Genetic Polymorphisms and Phenotypes in Different Ethnicities of Malaysian Breast Cancer Patients
Chin, Fee Wai
Chan, Soon Choy
Rahman, Sabariah Abdul
Akmal, Sharifah Noor
Rosli, Rozita
BREAST JOURNAL, 2016, 22 (01) : 54 - 62

← 1 2 3 4 5 →